230 related articles for article (PubMed ID: 12697876)
1. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
Van Veldhuizen PJ; Faulkner JR; Lara PN; Gumerlock PH; Goodwin JW; Dakhil SR; Gross HM; Flanigan RC; Crawford ED;
Cancer Chemother Pharmacol; 2005 Jul; 56(1):39-45. PubMed ID: 15791454
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer.
Dent SF; Arnold A; Stewart DJ; Gertler S; Ayoub J; Batist G; Goss G; Nevile A; Soulieres D; Jolivet J; McLntosh L; Seymour L
Lung; 2005; 183(4):265-72. PubMed ID: 16211462
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Roboz GJ; Giles FJ; Ritchie EK; Allen-Bard S; Curcio TJ; Wilkes MA; Park SL; Kantarjian HM; Faderl S; Ravandi F; Kelner MJ; Feldman EJ
J Clin Oncol; 2007 Jan; 25(1):10-5. PubMed ID: 17146106
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
Weinerman BH; Eisenhauer EA; Besner JG; Coppin CM; Stewart D; Band PR
Cancer Treat Rep; 1986 Jun; 70(6):751-4. PubMed ID: 3524824
[TBL] [Abstract][Full Text] [Related]
6. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Amato RJ; Morgan M; Rawat A
Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
Bélanger K; Moore M; Baker SD; Dionne J; Maclean M; Jolivet J; Siu L; Soulières D; Wainman N; Seymour L
J Clin Oncol; 2002 May; 20(10):2567-74. PubMed ID: 12011137
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of bortezomib for patients with advanced renal cell carcinoma.
Kondagunta GV; Drucker B; Schwartz L; Bacik J; Marion S; Russo P; Mazumdar M; Motzer RJ
J Clin Oncol; 2004 Sep; 22(18):3720-5. PubMed ID: 15365068
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide therapy for metastatic renal cell carcinoma.
Amato RJ; Hernandez-McClain J; Saxena S; Khan M
Am J Clin Oncol; 2008 Jun; 31(3):244-9. PubMed ID: 18525302
[TBL] [Abstract][Full Text] [Related]
12. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
[TBL] [Abstract][Full Text] [Related]
13. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Ratain MJ; Eisen T; Stadler WM; Flaherty KT; Kaye SB; Rosner GL; Gore M; Desai AA; Patnaik A; Xiong HQ; Rowinsky E; Abbruzzese JL; Xia C; Simantov R; Schwartz B; O'Dwyer PJ
J Clin Oncol; 2006 Jun; 24(16):2505-12. PubMed ID: 16636341
[TBL] [Abstract][Full Text] [Related]
14. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
Haas NB; Smith M; Lewis N; Littman L; Yeslow G; Joshi ID; Murgo A; Bradley J; Gordon R; Wang H; Rogatko A; Hudes GR
Clin Cancer Res; 2003 Jan; 9(1):109-14. PubMed ID: 12538458
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.
Amato R; Zhai J; Willis J; Saxena S; DeFoe M
Clin Genitourin Cancer; 2012 Sep; 10(3):153-8. PubMed ID: 22551785
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Giles FJ; Garcia-Manero G; Cortes JE; Baker SD; Miller CB; O'Brien SM; Thomas DA; Andreeff M; Bivins C; Jolivet J; Kantarjian HM
J Clin Oncol; 2002 Feb; 20(3):656-64. PubMed ID: 11821445
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
18. Troxacitabine: BCH 4556, SPD 758, Troxatyl.
Adis International Ltd
Drugs R D; 2003; 4(4):264-8. PubMed ID: 12848594
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
20. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
